Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW OKs Dupixent, Tecentriq, Lynparza, and More
The Ministry of Health, Labor and Welfare (MHLW) approved a throng of new medicines on January 19, including Sanofi’s eczema drug Dupixent (dupilumab), Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab), and AstraZeneca’s PARP inhibitor Lynparza (olaparib). Dupixent is a human monoclonal…
To read the full story
Related Article
- Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
- MHLW Advisory Panel Backs Otsuka’s Schizophrenia Med Brexpiprazole and More
December 5, 2017
- MHLW Panel Backs Approval for AZ’s Olaparib, Benralizumab and More
November 28, 2017
- Sanofi’s Dupilumab, Chugai’s PD-L1, Keytruda’s Lymphoma Use and More Clear MHLW Panel
November 7, 2017
- MHLW Advisory Panel Backs Nexium’s Pediatric Dosages, Oral Suspension Form
November 6, 2017
REGULATORY
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
- 3 Label Expansions Get NHI Coverage on Public Knowledge Pathway
July 29, 2026
- No Cap on FY2027 Budget Requests under Growth Investment Scheme: MOF
July 29, 2026
- Japan Panel Green-Lights GSK’s Hep B Drug, Brinsupri, Hyrnuo
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…